Part of your question is about the technicalities of operating reactors, and I would probably say that we are not the experts, so I'm not sure I can fully answer all of that.
In terms of what it takes to produce medical isotopes and our role in that, there's a lot of infrastructure required, clearly. We would be very open to looking at all options to ensure continuity of supply--let me state that--although we do have a contract with AECL, which we alluded to.
There are many requirements in terms of production, processing, safety, regulation, and logistics. This business has always had, I think, barriers to entry, and we don't have exclusivity in the market. What we do have, though, is a lot of know-how that we've built up over the years. I think it's very difficult to duplicate, frankly, and probably that's one of the reasons we are a great Canadian success story. We do have a lot of embedded knowledge. I assume that AECL also has a lot of embedded knowledge that it might be able to share.
When it comes to long-term supply and when it comes to the needs of patients and supplying our customers, I think we have to look at those options, and we're prepared to do so. It's not intuitive to me today what those options are. And it's not obvious to us that there are any other options today other than completing the MAPLE reactor. I want to be very clear about that.